**Name of journal: *World Journal of Gastroenterology***

**ESPS Manuscript NO: 35276**

**Manuscript Type: SYSTEMATIC REVIEWS**

**Vaccinations in immunosuppressive-dependent pediatric inflammatory bowel disease**

Nguyen HT *et al.* Vaccinations in pediatric IBD

Huyen-Tran Nguyen, Phillip Minar, Kimberly Jackson, Patricia C Fulkerson

**Huyen-Tran Nguyen, Patricia C Fulkerson,** Division of Allergy and Immunology, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, United States

**Phillip Minar, Kimberly Jackson,** Division of Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Cincinnati Children’s Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH 45229, United States

**ORCID number:** Huyen-Tran Nguyen (0000-0002-1067-2383); Phillip Minar (0000-0003-4223-4211); Kimberly Jackson (0000-0003-3013-0570); Patricia C Fulkerson (0000-0002-1512-8889).

**Author contributions:** Nguyen HT, Minar P, Jackson K, and Fulkerson PC designed the project. Nguyen HT, Minar P and Jackson K acquired data; Nguyen HT and Fulkerson PC analyzed and interpreted the data; all authors contributed to the drafting and revision of the manuscript; all authors also read and approved the final manuscript; all authors are native-English speakers.

**Conflict-of-interest statement:** All authors have no competing interests to declare.

**Data sharing statement:** De-identified data are available from the corresponding author at [Patricia.Fulkerson@cchmc.org](mailto:Patricia.Fulkerson@cchmc.org). This project was IRB approved (Study #2015-9400). The research was determined to be no more than minimal risk to participants so consent was waived. The data are anonymized and risk of identification is low.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to:** **Patricia C Fulkerson, MD, PhD, Assistant Professor,** Division of Allergy and Immunology, Cincinnati Children’s Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, 3333 Burnet Avenue, MLC 7028, Cincinnati, OH 45229, United States. patricia.fulkerson@cchmc.org

**Telephone:** +1-513-8030973

**Fax:** +1-513-6363310

**Received:** July 06, 2017

**Peer-review started:** July 06, 2017

**First decision:** July 28, 2017

**Revised:** August 14, 2017

**Accepted:** August 25, 2017

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To determine the vaccination rates in pediatric immunosuppression-dependent inflammatory bowel disease (IBD) and review the safety and efficacy of vaccinations in this population.

***METHODS***

The electronic medical records from October 2009 to December 2015 of patients diagnosed with IBD at 10 years of age or younger and prescribed anti-tumor necrosis factor alpha (anti-TNF-α) therapy were reviewed for clinical history, medication history, vaccination history, and hepatitis B and varicella titers. Literature discussing vaccination response in IBD patients were identified through search of the MEDLINE database and reviewed using the key words “inflammatory bowel disease”, “immunization”, “vaccination”, “pneumococcal”, “varicella”, and “Hepatitis B”. Non-human and non-English language studies were excluded. Search results were reviewed by authors to select articles that addressed safety and efficacy of immunizations in inflammatory bowel disease.

***RESULTS***

A total of 51 patients diagnosed with IBD prior to the age of 10 and receiving anti-TNF-α therapy were identified. Thirty-three percent of patients (17/51) had incomplete or no documentation of vaccinations. Sixteen case reports, cohort studies, cross-sectional studies, and randomized trials were determined through review of the literature to describe the safety and efficacy of Hepatitis B, pneumococcal, and varicella immunizations in adult and pediatric patients with IBD. These studies showed that patients safely tolerated the vaccines without significant adverse effects. Importantly, IBD patients receiving immunosuppressive medications, particularly anti-TNF-α treatment, have decreased vaccine response compared to controls. However, the majority of patients are still able to achieve protective levels of specific antibodies.

***CONCLUSION***

Immunizations have been shown to be well-tolerated and protective immunity can be achieved in patients with IBD requiring immunosuppressive therapy.

**Key words:** Vaccination; Immunosuppression; Early-onset inflammatory bowel disease; Very early-onset inflammatory bowel disease

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Chronic immunosuppression and immune defects can contribute to increased susceptibility to infections in pediatric inflammatory bowel disease (IBD). Immunization rates among IBD patients are low due to concerns about vaccine efficacy while on immunosuppression and disease exacerbation with administration. The aim of this review was to determine the vaccination rates in pediatric immunosuppression-dependent IBD and the safety and efficacy of immunizations in this population.

Nguyen HT, Minar P, Jackson K, Fulkerson PC. Vaccinations in immunosuppressive-dependent pediatric inflammatory bowel disease. *World J Gastroenterol* 2017; In press

**INTRODUCTION**

The prevalence of inflammatory bowel disease (IBD) is on the rise, particularly in the elderly population and very young children. Approximately 25% of patients with IBD will be diagnosed during childhood, and very early-onset IBD (VEOIBD) further classifies those children diagnosed before 6 years of age. VEOIBD comprises 15% of pediatric IBD cases and has an incidence rate of 4.37 per 100000 children and a prevalence of 14 per 100000 children[1]. The increasing incidence in the very young is of interest to immunologists as these patients often are referred for evaluation for immunodeficiency. Conventional, polygenic IBD predominates in patients aged 7 years and older at time of diagnosis, but approximately 20% of VEOIBD is monogenic-single gene defects that affect the gastrointestinal immune regulation. Mutations that result in chronic granulomatous disease, IL-10 signaling alterations, and defects in X-linked inhibitor of apoptosis function have been associated with VEOIBD[1]. These abnormalities in innate immunity are further compounded by immunosuppressive medications prescribed for IBD treatment, resulting in increased risk of infection. A cross-sectional analysis showed that bacterial pneumonia was one of the most common causes of hospitalizations for IBD patients on immunomodulators or anti–tumor necrosis factor alpha (antiTNF-alpha) therapy with a prevalence of *S. pneumoniae* pneumonia at 82.6 per 100000 compared to 69.2 per 100000 in controls[2]. Adult IBD patients have an increased risk of pneumonia (OR = 1.54, 95%CI: 1.49-1.60) compared to matched individuals without IBD with use of immunosuppressive therapies like biologics (OR = 1.32, 95%CI: 1.11-1.57) and corticosteroids (OR = 1.91, 95%CI: 1.72-2.12) as a risk factor[3]. VEOIBD children in particular are at increased risk for vaccine-preventable infections, as many may have not yet completed their primary vaccination series prior to starting immunosuppressive therapies such as immunomodulators or anti–TNF-α.

The Infectious Diseases Society of America recommends that patients with chronic inflammatory diseases treated with long-term immunosuppression receive inactive vaccinations, such as pneumococcal vaccines, per standard immunization schedules[4]. Despite these recommendations, vaccination rates among IBD patients are lower than expected. In a study of 169 adult IBD patients, only 10% of participants received recommended pneumococcal vaccines[5]. Common reasons among patients for decreased adherence with vaccination recommendations have included belief in poor efficacy of vaccines, lack of knowledge about vaccine guidelines, and fear of disease exacerbation with vaccine administration[5].

The primary aim of our study was to determine the vaccination rates among pediatric patients with immunosuppression-dependent IBD at our institution by retrospectively reviewing the electronic medical records from October 2009 through December 2015 at Cincinnati Children’s Hospital Medical Center (CCHMC). Additionally, we systematically reviewed the literature.

**MATERIALS AND METHODS**

***Determination of vaccination rates in pediatric IBD***

Pediatric patients with a diagnosis of IBD made prior to the age of 10 years and receiving anti–TNF-alpha were identified at CCHMC. We included patients diagnosed prior to age 10 to ensure capture of patients with possible monogenic disease. The electronic medical records for the patients, dated from October 2009 to December 2015, were retrospectively reviewed. Information including clinical history, exam findings, patient’s IBD status, results of esophagogastroduodenoscopy and/or colonoscopy with biopsies, vaccination records, medication records, vaccine titers, and infectious disease laboratory testing results were collected. This study was approved by the CCHMC Institutional Review Board.

***Literature review***

The MEDLINE database was searched through PubMed with search strategies as detailed in Table 1. Search results were reviewed by the primary research participants to determine if articles addressed safety and efficacy of immunizations in inflammatory bowel disease and other immunomodulator-dependent diseases. Articles were limited to randomized trials, case-control studies, cohort studies, and reviews. Childhood and adult immunizations to pneumococcal, Hepatitis B, and varicella with any dose and any schedule were included. Non-human and non-English language studies were excluded.

**RESULTS**

***Vaccination Rates in Immunosuppression-dependent pediatric IBD***

A total of 51 pediatric patients with a diagnosis of IBD made prior to the age of 10 years and receiving anti–TNF-α were identified. The age at diagnosis for these 51 patients ranged from 15 mo to 9 years of age. Sixty-seven percent (34/51) had documentation of a completed primary vaccination series (Figure 1A). The remainder of the patients had no or incomplete documentation of immunizations.

Hepatitis B (HepB) serology has been recommended prior to initiation of immunosuppressive therapies due to the risk of reactivation of latent HepB infection with the start of treatment[6,7]. Additionally, it is recommended that non-immune HepB patients receive a vaccine booster[8]. In our retrospective study, serology specifically evaluating HepB surface antibody showed that 67% (27/44 patients who had documented serology) were non-responders to their initial HepB vaccine series (Figure 1B). Six of the non-responders (6/27) had documentation of HepB vaccine booster receipt and post-vaccination titers drawn. Four of the 6 achieved seroprotection following the booster vaccine. Eighteen of the non-responders (18/27) either did not receive HepB vaccine booster or did not have repeat HepB titers measured.

With increasing use of immunomodulatory therapy in the management of IBD, evaluation of varicella immunity is also recommended as primary infection can be severe and life-threatening in immunocompromised hosts. Twenty-eight percent (9/32) of patients who had varicella antibodies measured had negative titers (Figure 1C). We found that 4 of the 9 patients had only one varicella vaccine administration documented.

***Safety and efficacy of inactive vaccines in pediatric IBD***

The efficacy of immunizations in patients with chronic inflammatory diseases requiring immunosuppressive therapies has been an area of concern. Studies involving rheumatologic disorders, such as rheumatoid arthritis and systemic lupus erythematous, have shown that immunizations are well tolerated and do not exacerbate disease activity[9,10]. Further studies demonstrate that patients with rheumatologic diseases receiving immunosuppressive therapies may have a decreased response to immunizations but are still able to mount a specific-antibody response to vaccinations[11-15]. Interestingly, Kapetanovic et al. proposed the possibility of anti–TNF-α therapy enhancing the immune response as IBD patients receiving anti-TNF monotherapy in this cohort had a serum response to pneumococcal polysaccharide vaccine (PPSV23) that was similar to that of healthy controls[16]. In addition, anti-pneumococcal protective titers were sustained as long as 10 years following administration of the PPSV23 in patients with autoimmune inflammatory disease[17]. In a randomized controlled study with 103 adult rheumatoid arthritis patients, the effects of systemic immunosuppression on vaccine responses were evaluated. Patients treated with both methotrexate and rituximab had decreased response to PPSV23, a T-independent antigen, compared to patients treated with methotrexate alone. However, over half of the patients receiving adjunctive therapy with rituximab responded to at least one of the pneumococcal serotypes. Additionally, there was no difference in response to the T-dependent antigens, such as the tetanus toxoid, between the two treatment groups[18]. These results support the increased antigenicity of and improved response to vaccines containing T-dependent antigens in patients with chronic inflammatory diseases receiving immunosuppressive therapy.

The vaccine response in adult IBD patients undergoing immunosuppressive therapies is similar to those of rheumatologic patients (Table 2). In general, adult IBD patients have decreased magnitude of response to PPSV23/pneumococcal conjugate (PCV13) and HepB vaccines, but most patients retain their specific antibody response and can attain protective titer levels. The main difference between the findings of vaccine efficacy studies in rheumatologic patients and IBD patients was that anti-TNF therapy was associated with a higher risk of reduced response. However, IBD patients receiving anti-TNF treatment were still able to achieve protective levels of specific antibodies. An accelerated, double-dose HepB immunization series has been shown to be efficacious, wherein patients receive double doses of the vaccine 3 times at one-month intervals[19]. When combined with booster immunization in non-responders, the majority of IBD patients can attain seroprotection[19]. Additionally, PCV13, a T-dependent vaccine, was associated with increased titers compared to PPSV23[20]. These findings also apply to the Hepatitis A vaccine[21]. Vaccinations were overall well-tolerated and were not associated with adverse reactions such as exacerbation of the underlying inflammatory disease[20,22-24].

The efficacy and safety of primary vaccinations in pediatric IBD patients has been investigated in a limited number of studies (Table 3). The Hepatitis A vaccine series is highly immunogenic in pediatric IBD patients with seroconversion rates over 90% and has no significant differences in response between case patients compared to healthy controls; the vaccine was also well tolerated[25-27]. The HepB series does not have the same immunogenicity as Hepatitis A (Table 3). Pediatric IBD patients were shown to have decreased seroconversion rate following the completion of the 3-dose series compared to controls, but the majority, over 70%, still seroconverted[27,28]. PCV13 is commonly encountered in pediatric clinics compared to PPSV23 since the conjugate vaccine is fundamental to the primary vaccine series. Banaszkiewics et al. demonstrated that pediatric IBD patients have a good response to PCV13, further supporting that T-cell immunity seems to be conserved in IBD patients receiving immunosuppressive therapy and that T-dependent vaccines may be preferential to T-independent vaccines in these patients[29].

***Safety and efficacy of live vaccines in pediatric IBD***

Live vaccines have long been contraindicated in immunocompromised hosts. However, with the immunocompromised state comes increased risk of contracting infections prevented by these vaccines. Herpes zoster can occur in 20%-50% of patients following bone marrow transplant[30]. Crohn’s disease (varicella OR = 12.75; 95%CI: 8.30-19.59; herpes zoster OR = 7.91; 95%CI: 5.60-11.18) and ulcerative colitis (varicella OR = 4.25; 95%CI: 1.98-9.12; herpes zoster OR = 3.90; 95%CI: 1.98-7.67) in pediatric patients have an increased association with hospitalizations for varicella or herpes zoster[30]; thus, there is great interest in determining whether live vaccines are safe for pediatric patients with IBD on immunosuppressive therapy. Lu and Bousvaros[32] illustrated the safety and efficacy of the varicella vaccine in IBD patients on immunosuppressive therapies in a case series report. Three of the patients were on 6-mercaptopurine and tolerated the varicella vaccine without issue, developing equivocal or greater immunity. Two patients received the varicella vaccine while on infliximab, albeit inadvertently, without issue and developed positive titers to the virus.

The safety of live vaccines in other pediatric populations receiving immunosuppression has been investigated. Sauerbrei *et al*[30] studied the efficacy and safety of the varicella vaccine in children after bone marrow transplant. Fifteen patients received the varicella vaccine 12-23 mo (median 18 mo) after transplant. Notably, the study participants were within 1-2 years of transplantation during which time some degree of immune dysfunction is expected, but they were not receiving immunosuppression and their lymphocyte counts had to be greater than 1000/microliters with T cell counts greater than 700/microliters. Importantly, no study participant experienced adverse events related to the varicella vaccine. Nine of the participants were seronegative prior to the vaccine, and 8 of the 9 seroconverted within 6 months of vaccine administration. The remaining patient required a second dose of the vaccine, after which seroconversion was achieved within 6 months. Only 3 study participants had unchanged titers. Machado *et al*[34] also demonstrated that the measles, mumps, rubella vaccine was overall well tolerated in bone marrow transplant patients[33]. In addition, the varicella vaccine was found to be safe in juvenile rheumatic patients receiving methotrexate or corticosteroids.

These results suggest that live vaccines may be tolerated in patients receiving long-term immunosuppressive therapies, particularly in those without severe immune defects. However, this topic remains controversial, and the support for administering live vaccines in patients receiving immunosuppressive therapies is very limited and consists of small cohort or case series studies. Further studies are needed to confirm the safety of live vaccinations in an immunosuppressed population, which would greatly benefit from them.

**DISCUSSION**

Children with a diagnosis of IBD early in life are at significant risk of infection due to their immunosuppression from both their underlying disease and treatment. These patients will require years, if not a lifetime, of immunosuppressive therapy, and such regimens may be started prior to completion of their primary vaccination series due to their young age at diagnosis, augmenting their risk of infection. IBD patients in general have decreased vaccinations rates[35]. Working with allergists and immunologists, a thorough auditing of immunizations and measurement of antibodies to vaccine-preventable microbes at time of diagnosis can be achieved. Further, immunologists can update immunizations and ensure appropriate antibody response to provide protection in this growing, vulnerable population. To assess seroconversion and seroprotection to an immunization, specific serum antibody levels measured prior to and approximately four to eight weeks following vaccine administration are recommended[36]. Although booster vaccinations or completion of immunizations may not be possible prior to starting immunosuppressive treatment, studies have shown that these patients can still mount an immune response to vaccines, particularly to T-dependent antigens, until seroprotective status is achieved. Optimal vaccination schedules and long-term immunogenicity of these vaccines remain to be studied in pediatric IBD patients. In addition, considering their unique immune dysregulation, further studies in the efficacy of immunizations in pediatric IBD patients, especially in the very young, are needed.

**COMMENTS**

***Background***

The population of young children affected by inflammatory bowel disease (IBD) is growing. This disease is oftentimes complicated by immune defects and long-term immunosuppressive therapy, resulting in an increased susceptibility to infections. Updating vaccines at diagnosis or before initiating chronic immunosuppressive therapy would be ideal; however, this is often not achievable due to young age and the necessity to initiate treatment imminently. Immunization rates among IBD patients are lower with the efficacy of immunizations while receiving immunosuppression and the fear of disease exacerbation after vaccine administration negatively impacting rates. The aim of this review is to determine the vaccination rates in pediatric immunosuppression-dependent IBD and the safety and efficacy of immunizations in this population.

***Research frontiers***

The prevalence of IBD is on the rise, particularly in very young children. Approximately 25% of patients with IBD will be diagnosed during childhood, and very early-onset IBD (VEOIBD) further classifies those children diagnosed before 6 years of age and comprises 15% of pediatric IBD cases. As elucidated by Uhlig *et al* in 2014, VEOIBD has been associated with single gene defects affecting the gastrointestinal immune regulation in 20% of cases. This emerging population has posed diagnostic and management challenges for both gastroenterologists and immunologists. In addition to innate immunity abnormalities, these patients require long-term immunosuppression, including anti-tumor necrosis factor alpha (anti-TNF-α) therapies, for treatment. These factors contribute to an increased risk of infection.

***Innovations and breakthroughs***

Due to the young age at the time of diagnosis, patients with VEOIBD may not be able to complete their primary vaccination series prior to initiation of immunosuppressive therapies, which further exacerbates the increased risk of infection. The rate of vaccinations in addition to the safety and efficacy of immunizations has been studied in adult and, to a lesser extent, pediatric IBD patients. Literature discussing vaccination response in IBD patients were identified through search of the MEDLINE database and reviewed by the authors.

***Applications***

This review shows that vaccinations are well-tolerated in IBD patients, and protective immunity can be achieved in those receiving immunosuppression. Immunologists can help provide an auditing of immunizations and can ensure appropriate antibody response to provide protection in this vulnerable population.

***Terminology***

VEOIBD classifies children diagnosed with IBD at age 6 years or younger and is associated with single gene defects affecting gastrointestinal immune regulation in 20% of cases. Anti-TNF-α therapies, which include infliximab and adalimumab, are monoclonal antibodies that inhibit the inflammatory cytokine tumor necrosis factor-alpha. Pneumococcal conjugate vaccine (PCV13) contains thirteen serotypes of pneumococcus and elicits an immune response dependent on T-cells. Pneumococcal polysaccharide vaccine (PPSV23) contains 23 pneumococcal serotypes and incites production of specific antibodies independent of T-cells.

***Peer-review***

In this systematic review, the authors detailed the safety and efficacy of vaccinations in pediatric IBD.

**REFERENCES**

1 **Uhlig HH**, Schwerd T, Koletzko S, Shah N, Kammermeier J, Elkadri A, Ouahed J, Wilson DC, Travis SP, Turner D, Klein C, Snapper SB, Muise AM; COLORS in IBD Study Group and NEOPICS. The diagnostic approach to monogenic very early onset inflammatory bowel disease. *Gastroenterology* 2014; **147**: 990-1007.e3 [PMID: 25058236 DOI: 10.1053/j.gastro.2014.07.023]

2 **Stobaugh DJ**, Deepak P, Ehrenpreis ED. Hospitalizations for vaccine preventable pneumonias in patients with inflammatory bowel disease: a 6-year analysis of the Nationwide Inpatient Sample. *Clin Exp Gastroenterol* 2013; **6**: 43-49 [PMID: 23818801 DOI: 10.2147/CEG.S42514]

3 **Long MD**, Martin C, Sandler RS, Kappelman MD. Increased risk of pneumonia among patients with inflammatory bowel disease. *Am J Gastroenterol* 2013; **108**: 240-248 [PMID: 23295276 DOI: 10.1038/ajg.2012.406]

4 **Rubin LG**, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. *Clin Infect Dis* 2014; **58**: e44-100 [PMID: 24311479 DOI: 10.1093/cid/cit684]

5 **Melmed GY**, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, Frenck RW, Targan SR, Vasiliauskas EA. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. *Am J Gastroenterol* 2006; **101**: 1834-1840 [PMID: 16817843 DOI: 10.1111/j.1572-0241.2006.00646.x]

6 **Esteve M**, Saro C, González-Huix F, Suarez F, Forné M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. *Gut* 2004; **53**: 1363-1365 [PMID: 15306601 DOI: 10.1136/gut.2004.040675]

7 **Ojiro K**, Naganuma M, Ebinuma H, Kunimoto H, Tada S, Ogata H, Iwao Y, Saito H, Hibi T. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. *J Gastroenterol* 2008; **43**: 397-401 [PMID: 18592158 DOI: 10.1007/s00535-008-2165-x]

8 **Lu Y**, Bousvaros A. Immunizations in children with inflammatory bowel disease treated with immunosuppressive therapy. *Gastroenterol Hepatol* (N Y) 2014; **10**: 355-363 [PMID: 25013388]

9 **Elkayam O**, Yaron M, Caspi D. Safety and efficacy of vaccination against hepatitis B in patients with rheumatoid arthritis. *Ann Rheum Dis* 2002; **61**: 623-625 [PMID: 12079904]

10 **Mercado U**. Why have rheumatologists been reluctant to vaccinate patients with systemic lupus erythematosus? *J Rheumatol* 2006; **33**: 1469-1471 [PMID: 16881104]

11 **Brezinschek HP**, Hofstaetter T, Leeb BF, Haindl P, Graninger WB. Immunization of patients with rheumatoid arthritis with antitumor necrosis factor alpha therapy and methotrexate. *Curr Opin Rheumatol* 2008; **20**: 295-299 [PMID: 18388521 DOI: 10.1097/BOR.0b013e3282ffdeca]

12 **Elkayam O**, Paran D, Caspi D, Litinsky I, Yaron M, Charboneau D, Rubins JB. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus. *Clin Infect Dis* 2002; **34**: 147-153 [PMID: 11740700 DOI: 10.1086/338043]

13 **Kasapçopur O**, Cullu F, Kamburoğlu-Goksel A, Cam H, Akdenizli E, Calýkan S, Sever L, Arýsoy N. Hepatitis B vaccination in children with juvenile idiopathic arthritis. *Ann Rheum Dis* 2004; **63**: 1128-1130 [PMID: 15308522 DOI: 10.1136/ard.2003.013201]

14 **Mease PJ**, Ritchlin CT, Martin RW, Gottlieb AB, Baumgartner SW, Burge DJ, Whitmore JB. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. *J Rheumatol* 2004; **31**: 1356-1361 [PMID: 15229957]

15 **Visvanathan S**, Keenan GF, Baker DG, Levinson AI, Wagner CL. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. *J Rheumatol* 2007; **34**: 952-957 [PMID: 17444589]

16 **Kapetanovic MC**, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis.*Rheumatology* (Oxford) 2006; **45**: 106-111 [PMID: 16287919 DOI: 10.1093/rheumatology/kei193]

17 **Broyde A,** Arad U, Madar-Balakirski N, Paran D, Kaufman I, Levartovsky D, Wigler I, Caspi D, Elkayam O. Longterm Efficacy of an Antipneumococcal Polysaccharide Vaccine among Patients with Autoimmune Inflammatory Rheumatic Diseases. *J Rheumatol* 2016; **43**: 267-72 [PMID: 26773117 DOI: 10.3899/jrheum.150397]

18 **Bingham CO 3rd**, Looney RJ, Deodhar A, Halsey N, Greenwald M, Codding C, Trzaskoma B, Martin F, Agarwal S, Kelman A. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. *Arthritis Rheum* 2010; **62**: 64-74 [PMID: 20039397 DOI: 10.1002/art.25034]

19 **Gisbert JP**, Villagrasa JR, Rodríguez-Nogueiras A, Chaparro M. Efficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. *Am J Gastroenterol* 2012; **107**: 1460-1466 [PMID: 23034605 DOI: 10.1038/ajg.2012.79]

20 **Kantso B,** Halkjaer SI, Thomsen OO, Belard E, Gottschalck IB, Jorgensen CS, Krogfelt KA, Slotved HC, Ingels H, Petersen AM. Immunosuppressive drugs impairs antibody response of the polysaccharide and conjugated pneumococcal vaccines in patients with Crohn's disease. *Vaccine* 2015; **33**: 5464-5469 [PMID: 26275480 DOI: 10.1016/j.vaccine.2015.08.011]

21 **Park SH**, Yang SK, Park SK, Kim JW, Yang DH, Jung KW, Kim KJ, Ye BD, Byeon JS, Myung SJ, Kim JH. Efficacy of hepatitis A vaccination and factors impacting on seroconversion in patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2014; **20**: 69-74 [PMID: 24284413 DOI: 10.1097/01.MIB.0000437736.91712.a1]

22 **Fiorino G**, Peyrin-Biroulet L, Naccarato P, Szabò H, Sociale OR, Vetrano S, Fries W, Montanelli A, Repici A, Malesci A, Danese S. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. *Inflamm Bowel Dis* 2012; **18**: 1042-1047 [PMID: 21674732 DOI: 10.1002/ibd.21800]

23 **Lee CK**, Kim HS, Ye BD, Lee KM, Kim YS, Rhee SY, Kim HJ, Yang SK, Moon W, Koo JS, Lee SH, Seo GS, Park SJ, Choi CH, Jung SA, Hong SN, Im JP, Kim ES; Korean Association for the Study of Intestinal Diseases (KASID) Study. Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. *J Crohns Colitis* 2014; **8**: 384-391 [PMID: 24144611 DOI: 10.1016/j.crohns.2013.09.022]

24 **Sempere L**, Almenta I, Barrenengoa J, Gutiérrez A, Villanueva CO, de-Madaria E, García V, Sánchez-Payá J. Factors predicting response to hepatitis B vaccination in patients with inflammatory bowel disease. *Vaccine* 2013; **31**: 3065-3071 [PMID: 23664999 DOI: 10.1016/j.vaccine.2013.04.059]

25 **Moses J**, Alkhouri N, Shannon A, Feldstein A, Carter-Kent C. Response to hepatitis A vaccine in children with inflammatory bowel disease receiving infliximab. *Inflamm Bowel Dis* 2011; **17**: E160 [PMID: 21953938 DOI: 10.1002/ibd.21892]

26 **Radzikowski A**, Banaszkiewicz A, Łazowska-Przeorek I, Grzybowska-Chlebowczyk U, Woś H, Pytrus T, Iwańczak B, Kowalska-Duplaga K, Fyderek K, Gawrońska A, Karolewska-Bochenek K, Kotowska M, Albrecht P. Immunogenecity of hepatitis A vaccine in pediatric patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2011; **17**: 1117-1124 [PMID: 20818674 DOI: 10.1002/ibd.21465]

27 **Urganci N**, Kalyoncu D. Immunogenecity of hepatitis A and B vaccination in pediatric patients with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* 2013; **56**: 412-415 [PMID: 23841120]

28 **Moses J**, Alkhouri N, Shannon A, Raig K, Lopez R, Danziger-Isakov L, Feldstein AE, Zein NN, Wyllie R, Carter-Kent C. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. *Am J Gastroenterol* 2012; **107**: 133-138 [PMID: 21876562 DOI: 10.1038/ajg.2011.295]

29 **Banaszkiewicz A**, Targońska B, Kowalska-Duplaga K, Karolewska-Bochenek K, Sieczkowska A, Gawrońska A, Grzybowska-Chlebowczyk U, Krzesiek E, Łazowska-Przeorek I, Kotowska M, Sienkiewicz E, Walkowiak J, Gregorek H, Radzikowski A, Albrecht P. Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine in Pediatric Patients with Inflammatory Bowel Disease. *Inflamm Bowel Dis* 2015; **21**: 1607-1614 [PMID: 25919976 DOI: 10.1097/MIB.0000000000000406]

30 **Sauerbrei A**, Prager J, Hengst U, Zintl F, Wutzler P. Varicella vaccination in children after bone marrow transplantation. *Bone Marrow Transplant* 1997; **20**: 381-383 [PMID: 9339753 DOI: 10.1038/sj.bmt.1700909]

31 **Adams DJ**, Nylund CM. Hospitalization for Varicella and Zoster in Children with Inflammatory Bowel Disease. *J Pediatr* 2016; **171**: 140-145 [PMID: 26826886 DOI: 10.1016/j.jpeds.2015.12.072]

32 **Lu Y**, Bousvaros A. Varicella vaccination in children with inflammatory bowel disease receiving immunosuppressive therapy. *J Pediatr Gastroenterol Nutr* 2010; **50**: 562-565 [PMID: 20639716 DOI: 10.1097/MPG.0b013e3181bab351]

33 **Machado CM**, de Souza VA, Sumita LM, da Rocha IF, Dulley FL, Pannuti CS. Early measles vaccination in bone marrow transplant recipients. *Bone Marrow Transplant* 2005; **35**: 787-791 [PMID: 15750610 DOI: 10.1038/sj.bmt.1704878]

34 **Pileggi GS**, de Souza CB, Ferriani VP. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. *Arthritis Care Res* (Hoboken) 2010; **62**: 1034-1039 [PMID: 20235203 DOI: 10.1002/acr.20183]

35 **Malhi G**, Rumman A, Thanabalan R, Croitoru K, Silverberg MS, Hillary Steinhart A, Nguyen GC. Vaccination in inflammatory bowel disease patients: attitudes, knowledge, and uptake. *J Crohns Colitis* 2015; **9**: 439-444 [PMID: 25908717 DOI: 10.1093/ecco-jcc/jjv064]

36 **Orange JS**, Ballow M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, Kumararatne D, Harville TO, Hesterberg P, Koleilat M, McGhee S, Perez EE, Raasch J, Scherzer R, Schroeder H, Seroogy C, Huissoon A, Sorensen RU, Katial R. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma &amp; Immunology. *J Allergy Clin Immunol* 2012; **130**: S1-24 [PMID: 22935624 DOI: 10.1016/j.jaci.2012.07.002]

37 **Robinson CL**, Romero JR, Kempe A, Pellegrini C; Advisory Committee on Immunization Practices (ACIP) Child/Adolescent Immunization Work Group. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2017. *MMWR Morb Mortal Wkly Rep* 2017; **66**: 134-135 [PMID: 28182607 DOI: 10.15585/mmwr.mm6605e1]

38 **Andrade P**, Santos-Antunes J, Rodrigues S, Lopes S, Macedo G. Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients. *J Gastroenterol Hepatol* 2015; **30**: 1591-1595 [PMID: 25967740 DOI: 10.1111/jgh.13001]

39 **Cossio-Gil Y**, Martínez-Gómez X, Campins-Martí M, Rodrigo-Pendás JÁ, Borruel-Sainz N, Rodríguez-Frías F, Casellas-Jordà F. Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination.*J Gastroenterol Hepatol* 2015; **30**: 92-98 [PMID: 25160690 DOI: 10.1111/jgh.12712]

40 **Cekic C**, Aslan F, Krc A, Gümüs ZZ, Arabul M, Yüksel ES, Vatansever S, Yurtsever SG, Alper E, Ünsal B. Evaluation of factors associated with response to hepatitis B vaccination in patients with inflammatory bowel disease. *Medicine* (Baltimore) 2015; **94**: e940 [PMID: 26039133 DOI: 10.1097/MD.0000000000000940]

41 **Ben Musa R**, Gampa A, Basu S, Keshavarzian A, Swanson G, Brown M, Abraham R, Bruninga K, Losurdo J, DeMeo M, Mobarhan S, Shapiro D, Mutlu E. Hepatitis B vaccination in patients with inflammatory bowel disease. *World J Gastroenterol* 2014; **20**: 15358-15366 [PMID: 25386085 DOI: 10.3748/wjg.v20.i41.15358]

42 **Altunöz ME**, Senateş E, Yeşil A, Calhan T, Ovünç AO. Patients with inflammatory bowel disease have a lower response rate to HBV vaccination compared to controls. *Dig Dis Sci* 2012; **57**: 1039-1044 [PMID: 22147248 DOI: 10.1007/s10620-011-1980-8]

43 **Melmed GY**, Agarwal N, Frenck RW, Ippoliti AF, Ibanez P, Papadakis KA, Simpson P, Barolet-Garcia C, Ward J, Targan SR, Vasiliauskas EA. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. *Am J Gastroenterol* 2010; **105**: 148-154 [PMID: 19755964 DOI: 10.1038/ajg.2009.523]

44 **Fallahi G**, Aghamohammadi A, Khodadad A, Hashemi M, Mohammadinejad P, Asgarian-Omran H, Najafi M, Farhmand F, Motamed F, Soleimani K, Soheili H, Parvaneh N, Darabi B, Nasiri Kalmarzi R, Pourhamdi S, Abolhassani H, Mirminachi B, Rezaei N. Evaluation of antibody response to polysaccharide vaccine and switched memory B cells in pediatric patients with inflammatory bowel disease. *Gut Liver* 2014; **8**: 24-28 [PMID: 24516697 DOI: 10.5009/gnl.2014.8.1.24]

**P-Reviewer:** Katsanos KH, Suzuki H, Rocha R **S-Editor:** Qi Y  **L-Editor: E-Editor:**

**Specialty type:** Gastroenterology and hepatology

**Country of origin:** United States

**Peer-review report classification**


Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0



**Figure 1 Completeness of primary immunization documentation (A) and immune response to hepatitis B (B) and varicella (C) vaccines.** Primary immunizations evaluated include: diphtheria, tetanus, pertussis (DTaP), inactivated poliovirus (IPV), pneumococcal (PCV), *Haemophilus influenzae* type B (Hib), hepatitis B (HepB), measles, mumps, rubella (MMR), and varicella (VZV). These vaccines have been recommended for persons 18 years and younger in the United States by the Centers for Disease Controls’ Advisory Committee on Immunization Practices[37]. Fifty-one patients were included in this study. Of the 17 patients who had incomplete or no immunization documentations, 3 had explanations for incomplete vaccinations-1 patient started on infliximab in infancy, 1 patient did not receive the 2nd MMR and VZV since infliximab started, and parents of 1 patient declined some vaccines.

**Table 1 Search strategies**

|  |  |  |
| --- | --- | --- |
| Search Terms | Search Limitation | Number of Search Results |
| “inflammatory bowel disease” + “immunization” | Limited to human species and English language | 436 |
| “inflammatory bowel disease” + “vaccination” | Limited to human species and English language | 284 |
| “inflammatory bowel disease” + “pneumococcal” | Limited to human species and English language | 44 |
| “inflammatory bowel disease” + “Hepatitis B” | Limited to human species and English language | 181 |
| “inflammatory bowel disease” + “varicella” | Limited to human species and English language | 68 |
| “immunosuppression” + “pneumococcal” | Limited to human species and English language | 191 |
| “immunosuppression” + “Hepatitis B” + “vaccination” | Limited to human species and English language | 141 |
| “immunosuppression” + “varicella” + “vaccination” | Limited to human species and English language | 71 |

**Table 2 Studies of efficacy and safety of pneumococcal and hepatitis B vaccines in adult inflammatory bowel disease patients receiving immunosuppressive therapy**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Author and Year | Study Design | Subjects (no.) | Comparison Groups | Outcome Measured | Adverse Events | Effects |
| Andrade *et al*[38] 2015 | Retrospective cohort | 217 | IBD patients treated with infliximab and/or azathioprine | Hepatitis B antibodies 1-3 mo after HepB series completion | No comment on adverse effects | Receipt of vaccination while under infliximab or azathioprine treatment resulted in decreased seroconversion (OR 17.6, 95%CI: 8.5-33.9 and OR 3.3, 95%CI: 1.6-9.1) |
| Cosio-Gil *et al*[39] 2015 | Retrospective cohort | 172 | IBD patients | Hepatitis B antibodies 1-3 mo after HepB series completion | No comment on adverse effects | 50.6% patients responded to 1st series (95%CI: 42.9-58.3)  66.8% patients responded to 1st or 2nd series (95%CI: 59.3-73.8)  Older age associated with decreased response (for patients > 55 years, OR 3.6, 95%CI: 1.3-10.2) |
| Cekic *et al*[40] 2015 | Retrospective cohort | 125 | IBD patients | Hepatitis B antibodies 1 month after HepB series completion | No comment on adverse effects | Age over 45 years, active disease, CD subtype, and immune suppression negatively impacted vaccine response |
| Ben Musa *et al*[41]  2014 | Retrospective, cross-sectional | 500 | IBD patients | Hepatitis B antibodies | No comment on adverse effects | Younger age associated with increased HepB vaccine response |
| Sempere *et al*[24] 2013 | Retrospective cohort | 105 | IBD patients | Hepatitis B antibodies 1-3 mo after HepB series completion | No significant adverse events associated with vaccination | Ileal CD (*P* = 0.01), long-standing IBD (*P* = 0.03), low albumin (*P* = 0.02), and systemic steroid use with more than one dose (*P* = 0.02) associated with decreased response |
| Altunoz *et al*[42] 2012 | Retrospective cohort | 211—159 patients with IBD, 52 healthy controls | IBD patients and healthy controls | Hepatitis B antibodies at least 1 month after HepB series completion | No comment on adverse events | Diagnosis of IBD overall (*P* < 0.001), male sex among IBD patients (*P* = 0.01), immunosuppressive therapy (*P* < 0.001), and active disease (*P* < 0.001) associated with decreased response |
| Gisbert *et al*[19]  2012 | Prospective cohort | 241 | IBD patients | Hepatitis B antibodies 1-3 mo after HepB series (accelerated schedule or double dose) completion | No direct comment on adverse events | Older age (OR 0.96, 95%CI: 0.94-0.98, *P* < 0.001) and anti-TNF therapy (OR 0.39, 95%CI: 0.20-0.76, *P* < 0.01) associated with decreased rate of seroconversion  65% of participants responded after the 1st or 2nd series |
| Kantsǿ *et al*[20]  2015 | Randomized trial | 157 | CD patients receiving PCV13 *vs* PPV23 | Specific antibody response to 12 pneumococcal serotypes 1 month after vaccination | No significant adverse events related to vaccination | PCV13 induced higher post-immunization titers for 5 serotypes (*P* < 0.05), regardless of treatment  Immunosuppressive treatment with or without anti–TNF-α impaired immune response to both vaccines |
| Lee *et al*[23]  2014 | Prospective cohort | 197 | CD patients | Antibody response 1 mo after PPSV23 | No serious adverse effects in study | Female gender and anti-TNF therapy (monotherapy or combination with immunomodulator) associated with decreased response |
| Fiorino *et al*[22] 2012 | Prospective cohort | 96 | IBD patients | Antibody response 3 wk after PPSV23 | No serious adverse effects in the study | Infliximab only and combination therapy associated with decreased response (*P* = 0.009 and *P* = 0.038, respectively) |
| Melmed *et al*[43]  2010 | Prospective cohort | 64—45 patients with IBD, 19 healthy controls | 1. IBD patients not receiving immunosuppressive therapy 2. IBD patients receiving immunosuppression 3. Healthy controls | Specific antibody response to 5 pneumococcal serotypes 4 weeks after PPSV23 | No comments on adverse effects | Combination immunosuppression associated with decreased response rate (*P* ≤ 0.01) |

CD: Crohn’s disease; HepB: Hepatitis B; IBD: Inflammatory bowel disease; PCV13: Pneumococcal conjugate vaccine; PPSV23: Pneumococcal polysaccharide vaccine; TNF: Tumor necrosis factor.

**Table 3 Studies of efficacy and safety of pneumococcal and hepatitis B vaccines in pediatric inflammatory bowel disease patients receiving immunosuppressive therapy**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Ref. | Study Design | Subjects (no.) | Comparison Groups | Outcome Measured | Adverse Effects | Effects |
| Urganci *et al*[27] 2013 | Prospective cohort | 97—47 with IBD, 50 healthy controls | IBD patients and healthy controls | Hepatitis A and Hepatitis B antibodies 1 month following Hepatitis A vaccine and HepB series | No severe adverse reactions associated with vaccination | All participants seroconverted to Hepatitis A  IBD patients had decreased seroconversion to Hepatitis B (70.2% *vs* 90% in healthy controls, *P* = 0.02)  No statistically significant association between treatment and vaccination response |
| Moses *et al*[27] 2012 | Prospective, cross-sectional | 100 IBD patients | IBD patients receiving infliximab | Hepatitis B immunity (anti-HBs ≥ 10 IU/mL) | No comments on adverse effects | Older age at diagnosis and study visit, pancolitis, and lower albumin levels associated with non-immunity (*P* < 0.05)  Infliximab dose, duration, frequency did not affect baseline immunity; associated with decreased immunity to booster |
| Fallahi *et al*[44] 2014 | Prospective cohort | 38—18 with IBD; 20 healthy controls | 1. IBD patients not receiving immunosuppressive therapy 2. IBD patients receiving immunosuppression 3. Healthy controls | Increase in total IgG 28 days after PPSV23 vaccination and percentage of switched memory B cells | No comments on adverse effects | IBD associated with decreased percentage of switched memory B cells and lower increase in total IgG level (*P* = 0.007 and *P* = 0.001, respectively) |
| Banaszkiewicz e *et al*[29] 2015 | Prospective cohort | 178—122 with IBD; 56 healthy controls | 1. IBD patients not receiving immunosuppressive therapy 2. IBD patients receiving immunosuppression 3. Healthy controls | Specific antibody response 6-8 weeks following 1 dose of PCV13 | No serious adverse effects related to PCV13 | Adequate vaccine response achieved in all participants (90.4% in IBD patients versus 96.5% in controls) with no significant difference between IBD patients and controls (*P* = 0.53)  Immunosuppressive therapy associated with decreased rise in geometric mean titers (*P* = 0.04) |

anti-HBs: anti-hepatitis B surface antibody; CD: Crohn’s Disease; HepB: Hepatitis B; IBD: Inflammatory bowel disease; PCV13: Pneumococcal conjugate vaccine; PPSV23: Pneumococcal polysaccharide vaccine; TNF: Tumor necrosis factor.